Provides clinical laboratory testing to physicians, hospitals and other health facilities, sells Rayaldee and NGENLA, and develops therapies for cancer and infectious diseases.
10-K for FY2025, filed Feb 26, 2026Our diagnostics business, BioReference Health, LLC (“BioReference”), is a highly specialized laboratory in the United States that we have…View ↗
Through our pharmaceutical business, we manufacture and sell Rayaldee, a U.S. Food and Drug Administration (“FDA”) approved treatment for…View ↗
Our subsidiary, ModeX Therapeutics, Inc. (“ModeX”), is a biotechnology company focused on developing innovative multi-specific immune…View ↗
Insurers, government programs and client institutions pay for laboratory testing when results are reported; customers pay for products when they obtain them. OPKO also grants royalty-bearing licenses to development partners.
10-K for FY2025, filed Feb 26, 2026Revenue for laboratory services is recognized at the time test results are reported, which approximates when services are provided and the…View ↗
Healthcare Insurers. Reimbursements from healthcare insurers are based on negotiated fee-for-service schedules. Revenues consist of amounts…View ↗
Government Payors. Reimbursements from government payors are based on fee-for-service schedules set by governmental authorities, including…View ↗
Client Payors. Client payors include physicians, hospitals, employers, and other institutions for which services are performed on a…View ↗
We recognize revenue from product sales when a customer obtains control of promised goods or services. The amount of revenue that is…View ↗
In March 2023, ModeX, OPKO, and Merck entered into a License and Research Collaboration Agreement (the “Merck Agreement”), pursuant to…View ↗
10-K for FY2025, filed Feb 26, 2026
FY2025 revenue by product or service ↗$606.9M
10-K for FY2025, filed Feb 26, 2026
$606.9M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Service
Usage-based
10-K for FY2025, filed Feb 26, 2026 |
61%
FY2022: 75%
|
Service, FY2025
$370.3M Sources
|
Usage-based |
|
Product
Sold outright
10-K for FY2025, filed Feb 26, 2026 |
26%
FY2022: 14%
|
Product, FY2025
$156.9M Sources
|
Sold outright |
|
Transfer of Intellectual Property and Other
Licensed
10-K for FY2025, filed Feb 26, 2026 |
13%
FY2022: 11%
|
Transfer of Intellectual Property and Other, FY2025
$79.7M Sources
|
Licensed |
BioReference markets tests directly to healthcare providers and facilities, including physician offices, hospitals, clinics and correctional facilities. Insurers and government programs reimburse tests; client institutions and patients are also billed.
10-K for FY2025, filed Feb 26, 2026Our diagnostics business, BioReference Health, LLC (“BioReference”), is a highly specialized laboratory in the United States, with a sales…View ↗
Healthcare Insurers. Reimbursements from healthcare insurers are based on negotiated fee-for-service schedules. Revenues consist of amounts…View ↗
Government Payors. Reimbursements from government payors are based on fee-for-service schedules set by governmental authorities, including…View ↗
Client Payors. Client payors include physicians, hospitals, employers, and other institutions for which services are performed on a…View ↗
Patients. Uninsured patients are billed based on established patient fee schedules or fees negotiated with physicians on behalf of their…View ↗
No. It lost $225.7M in FY2025.
10-Q for Q3 FY2026, filed Nov 4, 2026
−$53.5MView ↗
8-K, filed Jul 27, 2026
Expanded Nicoya Agreement to Support RAYALDEE® Commercialization in Greater China. Under the amended agreement, OPKO received a 15% equity…View ↗
Shrinking. Revenue fell 66% in 4 years, from $1.8B in FY2021 to $606.9M in FY2025, about 24% a year.
A narrower diagnostics business
The older report describes a broad, nationwide BioReference laboratory offering many types of testing; the latest report centers the remaining business on clinical and women's health testing in New York and New Jersey and a national urology franchise after asset sales.
10-K for FY2022, filed Feb 27, 2023 10-K for FY2025, filed Feb 26, 2026Our diagnostics business, BioReference Health, LLC (“BioReference”), is a highly specialized laboratory in the United States that we have…View ↗
Competes with Ascendis Pharma and Novo Nordisk
10-K for FY2025, filed Feb 26, 2026There are pharmaceutical and biopharmaceutical companies, including Ascendis Pharma A/S, a biopharmaceutical company, and Novo Nordisk A/S…View ↗
Loading...